Linked Life Data

Eculizumab

Source:http://linkedlifedata.com/resource/umls/id/C1541483

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
calbc:hasCorrelation
skos:definition
NCI: A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05),NCI: A monoclonal antibody used to prevent red blood cells from being destroyed in patients with paroxysmal nocturnal hemoglobinuria (PNH), a red blood cell disorder. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body. Eculizumab blocks a protein in the blood that causes the breakdown of red blood cells.,PDQ: A human monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. Check for "http://www.cancer.gov/Search/Clin
skos:inScheme
skos-xl:prefLabel
skos-xl:altLabel